Seeking Alpha·Sep 15, 2026
Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sight Sciences is exhibiting a promising revenue inflection, with growth accelerating to 19.5% year-over-year in 2026Q2 on the back of best-in-class 91.4% gross margins. However, this top-line momentum is not yet translating to profitability, as persistent ope...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.08+56.4% vs -$0.18 | $23M+7.7% vs $22M |
Q2 2026 May 6, 2026 | -$0.24-26.3% vs -$0.19 | $20M+6.7% vs $18M |
Q2 2026 Mar 4, 2026 | -$0.08+46.7% vs -$0.15 | $20M+0.2% vs $20M |
Q4 2025 Nov 6, 2025 | -$0.16+38.5% vs -$0.26 | $20M-2.2% vs $20M |
Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BlackRock Inc. acquired a new stake in Sight Sciences, Inc. (NASDAQ: SGHT) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,083,108 shares of the company's stock, valued at approximately $16,710,000. BlackRock Inc. owned approximately 5.67% of Sight Sciences
MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to state:
Benchmark SGHT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Sight Sciences, Inc. (SGHT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.50 | $462.48M | -11.49 | -3.13% | -49.67% | -50.74% | — | |
| $153.49 | $9.05B | -46.80 | 32.33% | -30.68% | -27.07% | — | |
| $59.96 | $3.05B | -249.81 | 14.88% | 1.85% | 2.14% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $179.95 | $9.42B | -64.27 | -27.1% | 4.9% | 9.08% | — |
Sight Sciences, Inc. (SGHT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Sight Sciences, Inc. (SGHT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Aug 5, 2026·SEC
Jun 5, 2026·SEC
Get notified when SGHT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Sight Sciences, Inc. (SGHT) stock FAQ — growth, dividends, profitability & financials explained
Sight Sciences, Inc. (SGHT) reported $83.4M in revenue for fiscal year 2025. This represents a 1007% increase from $7.5M in 2018.
Sight Sciences, Inc. (SGHT) saw revenue decline by 3.1% over the past year.
Sight Sciences, Inc. (SGHT) reported a net loss of $29.8M for fiscal year 2025.
Sight Sciences, Inc. (SGHT) has a return on equity (ROE) of -50.7%. Negative ROE indicates the company is unprofitable.
Sight Sciences, Inc. (SGHT) had negative free cash flow of $23.3M in fiscal year 2025, likely due to heavy capital investments.
